Payment overview · 2025
General Payments
$1,179.35
62 reported records · 13 companies
Healthcare provider profile · identity verified
Robert Fulop
Allopathic & Osteopathic Physicians|Internal Medicine · STATEN ISLAND, NY · NPI 1861461345
Verified facts
What the public records show
CMS Open Payments records show Robert Fulop received $1,179.35 in general payments during 2025 across 62 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $239.97 | 20.4% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $158.62 | 13.4% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $136.26 | 11.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $114.62 | 9.7% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $96.95 | 8.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.19 | 8.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $93.58 | 7.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $91.43 | 7.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.22 | 3.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.75 | 3.3% | 2 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $29.38 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.21 | 1.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.17 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,179.35 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $239.97 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $229.84 | 10 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $96.95 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $95.77 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $95.77 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $93.55 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $93.55 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $91.43 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $79.08 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $63.71 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.22 | 2 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $29.38 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.80 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 97 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 15 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
161 | 49 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 815 | 246 |
| Atorvastatin Calcium | Atorvastatin Calcium | 668 | 209 |
| Metoprolol Succinate | Metoprolol Succinate | 474 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 372 | 123 |
| Simvastatin | Simvastatin | 332 | 89 |
| Losartan Potassium | Losartan Potassium | 296 | 91 |
| Metformin Hcl | Metformin Hcl | 288 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 253 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 81 |
| Valsartan | Valsartan | 229 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 210 | 35 |
| Omeprazole | Omeprazole | 206 | 67 |
| Ezetimibe | Ezetimibe | 189 | 60 |
| Lisinopril | Lisinopril | 163 | 49 |
| Synthroid | Levothyroxine Sodium | 161 | 49 |
| Famotidine | Famotidine | 150 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 51 |
| Alprazolam | Alprazolam | 139 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 38 |
| Sertraline Hcl | Sertraline Hcl | 133 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 36 |
| Glimepiride | Glimepiride | 115 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 37 |
| Eliquis | Apixaban | 97 | 25 |
| Allopurinol | Allopurinol | 92 | 28 |
| Gabapentin | Gabapentin | 92 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 28 |
| Furosemide | Furosemide | 85 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 29 |
| Enalapril Maleate | Enalapril Maleate | 79 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 78 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 35 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 20 |
| Lorazepam | Lorazepam | 63 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 19 |
| Atenolol | Atenolol | 61 | 15 |
| Terazosin Hcl | Terazosin Hcl | 60 | 16 |
| Montelukast Sodium | Montelukast Sodium | 56 | 16 |
| Benazepril Hcl | Benazepril Hcl | 51 | 16 |
| Finasteride | Finasteride | 47 | 18 |
| Prednisone | Prednisone | 47 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 12 |
| Alendronate Sodium | Alendronate Sodium | 45 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 15 |
| Jardiance | Empagliflozin | 42 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Januvia | Sitagliptin Phosphate | 40 | 14 |
| Buspirone Hcl | Buspirone Hcl | 37 | 11 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | 15 |
| Trazodone Hcl | Trazodone Hcl | 36 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 35 | 13 |
| Rybelsus | Semaglutide | 35 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 34 | 19 |
| Carvedilol | Carvedilol | 33 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 24 |
| Ramipril | Ramipril | 32 | 11 |
| Diazepam | Diazepam | 31 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | 12 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Alclometasone Dipropionate | Alclometasone Dipropionate | 16 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Meloxicam | Meloxicam | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,179.35 · 62 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, AREXVY, BREZTRI, COMIRNATY, ELIQUIS, EVENITY, Exablate, INSPIRE, JARDIANCE, Kerendia, LAGEVRIO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error